content top

Bevacizumab for Subfoveal Choroidal Neovascularization in a Child

Poster Gavin Tan Introduction: Choroidal neovascularization (CNV) is rare but important cause of visual impairment in children. It is often idiopathic or secondary to inflammation, optic nerve head abnormalities or retinal dystrophies. There is a lack of clinical trials assessing the treatment of CNV in children. Methods: A 11-year-old boy with no past medical or ocular history presented with 3 months duration of reduced vision in his...

Read More

Intravitreal Injection of Bevacizumab for the Treatment of Inflammatory Choroidal Neovascularization

Salim Ben Yahia, Bechir Jelliti, Rim Kahloun, Rim Ghrissi, Salah Jenzeri, Moncef Khairallah (Monastir, Tunisia) Advantages: To manage inflammatory choroidal neovascularization (CNV) with intravitreal injection of bevacizumab, since conventional therapeutic options, including laser photocoagulation, surgery, corticosteroids, and verteporfin therapy, have potential limitations and are associated with a high rate of recurrences. Methods:...

Read More

Treatment of Non-AMD (Myopic, Inflammatory, Angioid Streak…) Subfoveal Choroidal New Vessels with Intravitreal Anti-VEGF Instead of Photodynamic Therapy

http://www.evrs.eu/medias/2008/congress/Treatment-of-Non-AMD-(Myopic,-Inflammatory,-Angioid-Streak…)-Subfoveal-Choroidal-New-Vessels-with-Intravitreal-Anti-VEGF-Instead-of-Photodynamic-Therapy.flv Catherine Favard, Martine Mauget-Faysse Advantages: Intravitreal anti-VEGF therapy appears very effective to treat AMD choroidal new vessels and shows no choroidal ischemia and does not induce VEGF upregulation when compared to photodynamic...

Read More

Safety and Efficacy of Intravitreal Bevacizumab for Subfoveal Choroidal Neovascularization in Pathologic Myopia

Myriam Lucia Hernandez-Rojas, MD (Mexico City, Jose Dalma- Weiszhausz, MD (MexicoCity, Mexico), Hugo Quiroz- Mercado, MD (Mexico City, Mexico), Jans Fromow-Guerra, MD, PhD (Mexico City, Mexico), Griselda Alvarez-Rivera, MD (Mexico City, Mexico), Maura Abraham-Marin, MD (Mexico City, Mexico), Adriana Solis-Vivanco, MD (Mexico City, Mexico), Elizabeth Reyna-Castelan, MD (Mexico City, Mexico), Jose Luis Guerrero-Naranjo,MD (Mexico City,...

Read More

The Effects of Combined Inhibition of Platelet-derived Growth Factor (PDGF-B) and VEGF-A Signaling in Murine Models of Ocular Neovascularization

http://www.evrs.eu/medias/2006/congress/The-Effects-of-Combined-Inhibition-of-Platelet-derived-Growth- Factor-(PDGF-B)-and-VEGF-A-Signaling-in-Murine-Models-of-Ocular-Neovascularization.swf Anthony P. Adamis, MD (New York, NY),* David R. Guyer, MD (New York, NY)* PURPOSE: While the inhibition of VEGF-A signaling can prevent new blood vessel growth in cancer and ocular pathologies, more mature vessels appear to be less susceptible. Since...

Read More

Intravitreal Bevacizumab as Isolated First Line Therapy in Patients with New Untreated Choroidal Neovascular Membranes

http://www.evrs.eu/medias/2006/congress/Intravitreal-Bevacizumab-as-Isolated-First-Line-Therapy-in-Patients-with-New-Untreated-Choroidal-Neovascular-Membranes.swf Alay S Banker, MD (Ahmedabad, India), Marisa Flores-Aguilar, MD (Tijuana, Mexico), J. Fernando Arevalo, MD, FACS (Caracas, Venezuela) PURPOSE: To determine results of intravitreal bevacizumab in patients with choroidal neovascular membranes (CNVMs) of different types and...

Read More
content top